Distal-less homeobox 2 (DLX2) (DLX2)

Distal-less homeobox 2 (DLX2) is a critical homeobox transcription factor primarily involved in the embryonic development of the forebrain and craniofacial structures [1.3.1, 1.3.5]. It plays an essential role in the differentiation of GABAergic interneurons and the patterning of the branchial arches, which are vital for proper skull and facial formation [1.3.5, 1.4.1]. In adult tissues, DLX2 is often dysregulated in various malignancies, including gastric cancer, hepatocellular carcinoma, and glioblastoma, where it functions as an oncogene by promoting the epithelial-mesenchymal transition (EMT) and cell proliferation [1.1.1, 1.5.2, 1.5.3]. High expression of DLX2 is frequently associated with poor clinical outcomes and resistance to targeted therapies such as sorafenib [1.5.2]. Although direct small-molecule inhibitors of DLX2 are not currently available for clinical use, it is a significant target for experimental therapies, including RNA interference and the modulation of its associated signaling pathways like PI3K/AKT and TGF-beta [1.1.1, 1.2.1].

Other names

TES-1TES1Homeobox protein DLX-2Distal-less homeo box 2Dlx-2

DLX2 is targeted primarily through the modulation of its upstream regulatory pathways (e.g., PI3K/AKT, TGF-beta, Hedgehog) or via direct knockdown using RNA interference (siRNA/shRNA) to inhibit its oncogenic functions such as EMT induction and cell cycle progression [1.1.1, 1.2.1, 1.5.2].